Form 4: Oragenics Director John Gandolfo Awarded Options

Director John Gandolfo receives options to purchase 45,000 shares of Oragenics Inc. common stock.

Summary

• John Gandolfo, a director of Oragenics Inc., was granted options to purchase 45,000 shares of the company's common stock on September 19, 2024.
• The options were awarded under the company's 2021 Equity Incentive Plan as part of the non-employee director compensation program.
• The exercise price of the options is $0.48, which is the closing price of Oragenics' stock on the grant date.
• The options vest immediately and expire on September 19, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reflects a standard compensation practice. The option grant itself is neither particularly positive nor negative.

Positives

• The immediate vesting of the options provides an immediate incentive for the director.
• The grant aligns the director's interests with those of the shareholders.

Industry Context

Option grants to directors are a common practice in publicly traded companies as part of their compensation packages to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across industries and company sizes.
• Comparing Oragenics' director compensation to similar biotech companies would provide a better benchmark.
• Factors such as company performance, board responsibilities, and industry practices influence the size and structure of these grants.

Stakeholder Impact

• The option grant could potentially incentivize the director to act in ways that increase shareholder value.
• The dilution effect of the options is minimal given the relatively small number of shares involved.

Key Dates

Keywords

Oragenics, Director, Options, Equity Incentive Plan, Compensation, OGEN, Gandolfo